Table 22.

Statements pertaining chemoprevention in familial adenomatous polyposis—extended version

Statements
CP.1 Does chemoprevention prevent the occurrence of colorectal cancer? Currently, there are insufficient data to draw definitive conclusions regarding the effect of chemoprevention on the occurrence of colorectal cancer.
CP.2 Does chemoprevention prevent the occurrence of small bowel cancer? There is currently no available evidence indicating that chemoprevention prevents the occurrence or progression of small bowel cancer.
CP.3 Does chemoprevention prevent the occurrence of gastric cancer? The effect of chemoprevention on the occurrence of gastric cancer has not been investigated so far.
CP.4 Is chemoprevention effective in decreasing/regressing the size and number of polyps in the colorectum? Currently, there is insufficient evidence to support the recommendation of chemoprevention for reducing the number and/or size of colorectal polyps in clinical practice. The use of chemoprevention in this context can only be suggested within the framework of clinical trials.
CP.5 Does chemoprevention lead to a decrease in polyp size and number in the duodenum? There is currently insufficient evidence to support the recommendation of any chemopreventive agent for decreasing polyp size and number in the duodenum due to the lack of an acceptable risk/benefit ratio. Further trials with appropriate clinically meaningful endpoints are necessary.
CP.6 Does chemoprevention delay or prevent colectomy in FAP patients? There is no evidence to support the role of chemoprevention in delaying or preventing colectomy in FAP patients.
CP.7 Does chemoprevention delay or prevent risk-reducing surgery in the upper GI tract (pancreas-sparing or pancreatico-duodenectomy) in FAP patients? Chemoprevention does not delay or prevent risk-reducing surgery in the upper GI tract.

FAP, familial adenomatous polyposis; GI, gastrointestinal.